Citadel Advisors
MBIO icon

Citadel Advisors’s Mustang Bio MBIO Stock Holding History

Citadel Advisors’s Portfolio MBIO Stock Details MBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Hold
0
– -$110 – 14873
2023
Q1 		– Sell
-31
Closed -$12.7K – 14582
2022
Q4 		$9.24K Buy
31
+13
+72% +$4.44K ﹤0.01% 13697
2022
Q3 		$6K Sell
18
-90
-83% -$41.7K ﹤0.01% 12348
2022
Q2 		$47K Buy
108
+18
+20% +$9.96K ﹤0.01% 11971
2022
Q1 		$68K Buy
90
+33
+58% +$27.1K ﹤0.01% 12596
2021
Q4 		$71K Sell
57
-60
-51% -$96.9K ﹤0.01% 13016
2021
Q3 		$236K Buy
117
+44
+60% +$94.5K ﹤0.01% 11603
2021
Q2 		$183K Sell
73
-56
-43% -$137K ﹤0.01% 12263
2021
Q1 		$322K Sell
129
-72
-36% -$214K ﹤0.01% 10684
2020
Q4 		$570K Buy
201
+102
+103% +$244K ﹤0.01% 7902
2020
Q3 		$234K Buy
99
+69
+230% +$170K ﹤0.01% 8569
2020
Q2 		$72K Buy
+30
New +$70.1K ﹤0.01% 9142

Other funds holding MBIO

KAS
Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CG
CFO4Life Group Coppell, Texas $656M AUM 17.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Citadel Advisors's MBIO Position: Q1 2026 in Review

Citadel Advisors reduced its Mustang Bio (MBIO) stake by 37% in Q1 2026, selling an estimated $29.7K and leaving 53,200 shares worth $38.7K. The position accounts for ﹤0.01% of the portfolio, ranked #12498.

Citadel Advisors first reported a position in MBIO in Q3 2018 and has held it in 20 quarters since. The position peaked at $679K in Q3 2020. 22 funds tracked by Wall St. Rank hold MBIO as of Q1 2026.

  • Citadel Advisors held 53,200 shares of Mustang Bio worth $38.7K as of Q1 2026.
  • Citadel Advisors sold 31,565 Mustang Bio shares in Q1 2026, an estimated $29.7K.
  • Mustang Bio made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12498 holding.
  • Citadel Advisors first reported a position in Mustang Bio in Q3 2018 and has held it in 20 quarters since.
  • Citadel Advisors's Mustang Bio position peaked at $679K in Q3 2020.
  • 22 funds tracked by Wall St. Rank held Mustang Bio as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.